PMID- 38006346
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20240119
IS  - 0971-5916 (Print)
IS  - 0975-9174 (Electronic)
IS  - 0971-5916 (Linking)
VI  - 158
IP  - 4
DP  - 2023 Oct 1
TI  - Modulation of semaphorin 3C & 4D expression in cancerous tissues from individuals 
      with laryngeal squamous cell carcinoma.
PG  - 432-438
LID - 10.4103/ijmr.ijmr_3148_21 [doi]
AB  - BACKGROUND OBJECTIVES: Semaphorins were initially characterized as axon guidance 
      factors but were subsequently implicated in the regulation of immune responses, 
      angiogenesis, organ formation and a variety of other physiological and 
      developmental functions. Various semaphorins enhance or inhibit tumour 
      progression through different mechanisms. The objective of this study was to 
      assess the expression of various semaphorins and vascular endothelial growth 
      factor (VEGF) gene transcripts as well as the serum level of Sema3A in 
      individuals with laryngeal squamous cell carcinoma (LSCC). METHODS: Tissue 
      expression of Sema3A, Sema3C, Sema4D, Sema6D and VEGF was determined in both 
      tumour tissues and tissues around the tumour from 30 individuals with 
      pathologically confirmed LSCC using quantitative real-time PCR. Furthermore, the 
      serum level of Sema3A in these individuals was assessed using enzyme-linked 
      immunosorbent assay. RESULTS: Sema3C gene transcript showed a significant 
      increase (P=0.001), while Sema4D was observed with a significant decrease in 
      tumour samples compared to non-tumoural tissues (P</=0.01). The expression of the 
      Sema3C gene was found to be associated with the stage of LSCC tumour as it was 
      statistically significant for tumours with stage IV (P<0.01). The serum level of 
      Sema3A was not found to be significant between cases and controls. INTERPRETATION 
      CONCLUSIONS: Increased expression of Sema3C but decreased expression of Sema4D in 
      tumour tissue of LSCC may introduce these two growth factors as crucial mediators 
      orchestrating tumour growth in individuals with LSCC. This result could open a 
      new vision for the treatment of this malignancy.
CI  - Copyright (c) 2023 Copyright: (c) 2023 Indian Journal of Medical Research.
FAU - Sajadian, Marzieh
AU  - Sajadian M
AD  - Department of Immunology, School of Medicine, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Khademi, Bijan
AU  - Khademi B
AD  - Research Center of Otolaryngology Head & Neck Surgery, School of Medicine, Shiraz 
      University of Medical Sciences, Shiraz, Iran.
AD  - Department of Otolaryngology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Moinzadeh, Leila
AU  - Moinzadeh L
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
AD  - Department of Tissue Engineering & Applied Cell Sciences, School of Advanced 
      Medical Sciences & Technologies, Shiraz University of Medical Sciences, Shiraz, 
      Iran.
FAU - Ghaderi, Abbas
AU  - Ghaderi A
AD  - Department of Immunology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
AD  - Department of Tissue Engineering & Applied Cell Sciences, School of Advanced 
      Medical Sciences & Technologies, Shiraz University of Medical Sciences, Shiraz, 
      Iran.
FAU - Jafarzadeh, Abdollah
AU  - Jafarzadeh A
AD  - Department of Immunology, School of Medicine, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Razmkhah, Mahboobeh
AU  - Razmkhah M
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
AD  - Department of Tissue Engineering & Applied Cell Sciences, School of Advanced 
      Medical Sciences & Technologies, Shiraz University of Medical Sciences, Shiraz, 
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20230925
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Semaphorin-3A)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Semaphorins)
SB  - IM
MH  - Humans
MH  - Semaphorin-3A/genetics/metabolism
MH  - Vascular Endothelial Growth Factor A
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - *Semaphorins/genetics/metabolism
MH  - *Head and Neck Neoplasms
PMC - PMC10793821
COIS- None.
EDAT- 2023/11/26 07:42
MHDA- 2023/11/27 16:18
PMCR- 2023/10/01
CRDT- 2023/11/25 09:03
PHST- 2021/10/27 00:00 [received]
PHST- 2023/11/27 16:18 [medline]
PHST- 2023/11/26 07:42 [pubmed]
PHST- 2023/11/25 09:03 [entrez]
PHST- 2023/10/01 00:00 [pmc-release]
AID - 02223309-202310000-00015 [pii]
AID - IJMR-158-432 [pii]
AID - 10.4103/ijmr.ijmr_3148_21 [doi]
PST - ppublish
SO  - Indian J Med Res. 2023 Oct 1;158(4):432-438. doi: 10.4103/ijmr.ijmr_3148_21. Epub 
      2023 Sep 25.